Aberdeen Group’s Esperion Therapeutics ESPR Stock Holding History

Aberdeen Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-31,264	Closed	-$1.25M	–	929
2019 Q1	$1.25M	Buy	+31,264	New	+$1.4M	﹤0.01%	781

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Aberdeen Group's ESPR Position: Q2 2019 in Review

Aberdeen Group sold out of Esperion Therapeutics (ESPR) in Q2 2019, closing a stake of 31,264 shares — an estimated $1.25M sold.

Aberdeen Group first reported a position in ESPR in Q1 2019 and held it in 1 quarter. The position peaked at $1.25M in Q1 2019. 167 funds tracked by Wall St. Rank hold ESPR as of Q2 2019.

Aberdeen Group reported no remaining Esperion Therapeutics position as of Q2 2019 after selling out during the quarter.
Aberdeen Group sold 31,264 Esperion Therapeutics shares in Q2 2019, an estimated $1.25M.
Aberdeen Group first reported a position in Esperion Therapeutics in Q1 2019 and held it in 1 quarter.
Aberdeen Group's Esperion Therapeutics position peaked at $1.25M in Q1 2019.
167 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2019.

Based on Aberdeen Group's 13F filing for Q2 2019, filed 13 Aug 2019.